Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synmosa BiopharmaROCO:4114 +0.51%84 EV-to-EBITDA is 13.82 as of Sep. 21, 2026, which is 22% below its 10-year median of 17.65. GuruFocus rates ROCO:4114 with a GF Score™ of 84/100 and a GF Value™ of NT$34.27 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 746 Drug Manufacturers companies, Synmosa Biopharma ranks worse than 54.16% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Synmosa Biopharma's enterprise value is NT$16,982 Mil.
Synmosa Biopharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$1,229 Mil. Therefore, Synmosa Biopharma's EV-to-EBITDA for today is 13.82.
The historical rank and industry rank for Synmosa Biopharma's EV-to-EBITDA or its related term are showing as below:
ROCO:4114'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.73 Med: 17.65 Max: 5814.42
Current: 14.17
During the past 13 years, the highest EV-to-EBITDA of Synmosa Biopharma was 5814.42. The lowest was 11.73. And the median was 17.65.
ROCO:4114's EV-to-EBITDA is ranked worse than 54.16% of 746
companies
in the Drug Manufacturers industry
Industry Median: 12.395
vs ROCO:4114: 14.17
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Synmosa Biopharma's PE Ratio (TTM) for today is calculated as:
Synmosa Biopharma's share price for today is NT$29.80.
Synmosa Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.492.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Synmosa Biopharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Synmosa Biopharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synmosa Biopharma EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Synmosa Biopharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Synmosa Biopharma's EV-to-EBITDA falls into.
Synmosa Biopharma's current Enterprise Value is NT$16,982 Mil.
Synmosa Biopharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,229 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synmosa Biopharma (ROCO:4114) has a EV-to-EBITDA of 13.82 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Synmosa Biopharma. This is 22% below median its historical median of 17.65. Over the past decade, Synmosa Biopharma's EV-to-EBITDA has ranged from 11.73 to 5,814.42. According to the industry distribution chart, Synmosa Biopharma ranks #404 out of 746 companies in the Drug Manufacturers industry, placing it in the top 54.2%.
Is Synmosa Biopharma's EV-to-EBITDA too high?
Synmosa Biopharma's current EV-to-EBITDA of 13.82 is 22% below median its 10-year median of 17.65. Over the past 10 years, this metric has ranged from a low of 11.73 to a high of 5,814.42. The Drug Manufacturers industry median EV-to-EBITDA is 12.40. Synmosa Biopharma's value of 13.82 is 11.5% above this industry median. Based on the distribution chart, Synmosa Biopharma ranks #404 out of 746 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Synmosa Biopharma has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Synmosa Biopharma's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Synmosa Biopharma ranks #404 out of 746 companies for EV-to-EBITDA. This places Synmosa Biopharma in the lower half of its industry. The industry median EV-to-EBITDA is 12.40. Synmosa Biopharma's value of 13.82 is 11.5% above this benchmark. Historically, Synmosa Biopharma's own EV-to-EBITDA has ranged from 11.73 to 5,814.42 over the past decade. While the company's 10-year median is 17.65 vs. the industry median of 12.40, Synmosa Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.40, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synmosa Biopharma's current EV-to-EBITDA of 13.82 is 11.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Synmosa Biopharma. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synmosa Biopharma's current EV-to-EBITDA is 13.82, which is 22% below median its own 10-year median of 17.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synmosa Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Synmosa Biopharma (ROCO:4114) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$34.27, compared to a current price of NT$29.80 — trading 13% below its estimated fair value. The current EV-to-EBITDA is 13.82, which is 22% below median its 10-year median of 17.65 and 11.5% above the Drug Manufacturers industry median of 12.40. Synmosa Biopharma's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Synmosa Biopharma (ROCO:4114), the current EV-to-EBITDA is 13.82 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synmosa Biopharma (ROCO:4114) Overvalued in 2026?
Based on GuruFocus' analysis, Synmosa Biopharma stock appears to be undervalued.
The current stock price of NT$29.80 is trading 13% below its estimated GF Value™ of NT$34.27.
GuruFocus considers Synmosa Biopharma to be Modestly Undervalued.
Key valuation signals for ROCO:4114:
EV-to-EBITDA: 13.82 (22% below median its 10-year median of 17.65)
GF Value™: NT$34.27 vs. price of NT$29.80 (13% below fair value)
Industry Position: 11.5% above the Drug Manufacturers median (#404 of 746)
No single metric tells the full story. See the ROCO:4114 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synmosa Biopharma Corp is engaged in pharmaceuticals and medical devices, cosmetics, animal drugs, chemical food additives, beverages manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. Its segments include the Active Pharmaceutical Ingredients segment and the Generic Drugs segment. The Generic Drugs segment derives the majority of the revenue.
84GF Score
Get the complete analysis for ROCO:4114
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4114 has been successfully added to your 
